Merck, Keytruda and Neck Cancers
Merck expects oncology king Keytruda to face IRA 'price setting' process starting in 2026
Merck is bracing for the years of sales growth from oncology superstar Keytruda to take a sharp turn in 2028—and for more reasons than one. | The government price negotiations affecting Keytruda wouldn't take effect until 2028,
We recently published a list of the 10 Best Vaccine Stocks to Buy According to Hedge Funds. In this article, we are going to ...
As Merck & Co. hunts for an ideal spot to set up a new commercial facility, Delaware is looking to bolster its odds with a ...
Merck & Co. and Glenmark Pharmaceuticals Ltd. failed to convince a federal judge to toss antitrust claims tied to an alleged ...
We recently published a list of 10 Best Magic Formula Stocks for 2025. In this article, we are going to take a look at where ...
While Merck reported strong financial results in recent quarters, it faces both upsides and risks in the future. Read why I'm ...
Drug Maker Merck expects to boost employment in India with increment in its workforce across its India sites by the end of ...
COLORADO SPRINGS—Sierra Space has announced pharmaceutical giant Merck as its first commercial rideshare partner for the ...
We recently compiled a list of the 10 Cheap Pharmaceutical Stocks to Buy According to Analysts. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against ...
Drugmaker Merck , known as MSD outside of the U.S. and Canada, expects to increase its workforce across its India sites by ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback